Baseline clinical disease activity was significantly higher than in the IBD-only controls, with concomitant elevations in biomarkers including monocytosis, eosinophilia, elevated C-reactive protein and elevated erythrocyte sedimentation rate. The gene discussed is CRP; the disease is inflammatory bowel disease.